Indium (111In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer. Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA. Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single-photon emission computed tomography (SPECT).
|Target||Glutamate carboxypeptidase II|
|(what is this?) (verify)|
Early trials with yttrium (90Y) capromab pendetide were also conducted.
- ^ a b Manyak MJ (February 2008). "Indium-111 capromab pendetide in the management of recurrent prostate cancer". Expert Review of Anticancer Therapy. 8 (2): 175–81. doi:10.1586/14737188.8.131.52. PMID 18279057. S2CID 30587577.
- ^ WHO Drug Information
- ^ Kahn D, Austin JC, Maguire RT, Miller SJ, Gerstbrein J, Williams RD (April 1999). "A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy". Cancer Biotherapy & Radiopharmaceuticals. 14 (2): 99–111. doi:10.1089/cbr.1999.14.99. PMID 10850293.